- COSMO ANNOUNCES FULL-YEAR RESULTS 2021; CONFIRMS BEATING GUIDANCE
- First U.S. trial using GI Genius(TM) intelligent endoscopy module shows 50% reduction in missed colorectal polyps with Artificial Intelligence (AI) technology versus standard colonoscopy
- Invitation to Cosmo's full-year 2021 results and 2022 outlook webcast presentation on 23 March 2022
As of last trade
Cosmo Pharmaceuticals NV (CMOPF:PKL) traded at 47.50, 0.00% above its 52-week low of 47.50, set on May 09, 2022.
47.50May 09 202298.00Jun 15 2021
Markit short selling activity
|Market cap||894.92m CHF|
|EPS (TTM)||1.04 |
Data delayed at least 15 minutes, as of May 09 2022.